Phentermine + topiramate
Phentermine + topiramate has been studied in 38 papers since 2017: 1 trial and 9 observational studies in people, 27 reviews; 16 in the past year. It is an approved medicine. The newest paper, Nov 2, 2026: “Weight-Loss-Enriched Reverse Cardiac Remodeling After Semaglutide and Tirzepatide Initiation on Longitudinal Echocardiography”.
38 papers study it13 more mention it8 findingsUpdated
3 new papers in 30 daysSee all 51 papers on phentermine + topiramate
At a glance
Independent labs found the same change in people. 3 independent labs in 2 countries; 23 trials, none about aging, 4 with no results posted.
“At 12 months, weight loss was 15.32 kg versus 5.85 kg, respectively (mean difference -9.48 kg; p < 0.001).”
None of its findings points the other way.
- 3 independent labs in 2 countries
- 23 trials, none about aging, 4 with no results posted
- Funders: VIVUS and 1 more
- 2 of 7 findings with company ties
- 10 of 23 trials sponsored by its developers
- Human trial1
- Humans9
- In silico1
Studies in people
1 study gave phentermine + topiramate to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases body weight-9.48 kg down: Decreases Atherosclerotic Cardiovascular Disease Risk Score-3.35% | Randomized trial12 months | 80 peoplePatient cohorts | Obesity (Silver Spring, Md.), Jan 21, 2026 |
What did studies of phentermine + topiramate find?
6Studies of phentermine + topiramate measured 6 outcomes; the most studied is body weight (3 studies).
Body weight
downin humans3−7.9%
3 studies
Body weight
downin humans3−7.9%
Phentermine + topiramate decreases body weight in humans (-9.48 kg).
“At 12 months, weight loss was 15.32 kg versus 5.85 kg, respectively (mean difference -9.48 kg; p < 0.001).”
Human trial12 monthsn = 80
Obesity (Silver Spring, Md.)
Phentermine + topiramate is linked with lower body weight in humans (-1.59 percentage points).
“Phentermine/topiramate showed greater mean percentage weight loss at 6 months than orlistat (adjusted difference, -1.59 percentage points; p < 0.001)”
Humans6 months
Translational and clinical pharmacology
Phentermine + topiramate is linked with lower body weight in humans (-7.9%).
“At 5-6 months, the mean weight reduction was 7.9%”
Humans5-6 monthsn = 1,839
Diabetes, obesity & metabolism
Atherosclerotic Cardiovascular Disease Risk Score
downin humans1−3.4%
1 study
Atherosclerotic Cardiovascular Disease Risk Score
downin humans1−3.4%
Phentermine + topiramate decreases Atherosclerotic Cardiovascular Disease Risk Score in humans (-3.35%).
“Participants receiving phentermine-topiramate-ER experienced a 3.35% reduction in the estimated atherosclerotic CVD risk compared to baseline (p = 0.004).”
Human trial12 monthsn = 42
Obesity (Silver Spring, Md.)
Systolic blood pressure
downin humans1
1 study
Systolic blood pressure
downin humans1
Phentermine + topiramate is linked with lower systolic blood pressure in humans (-6 ± 15 mmHg, p < 0.001).
“systolic blood pressure by 6 ± 15 mmHg (all p < 0.001)”
Humans5-6 months
Diabetes, obesity & metabolism
Low-density lipoprotein cholesterol
downin humans1
1 study
Low-density lipoprotein cholesterol
downin humans1
Phentermine + topiramate is linked with lower low-density lipoprotein cholesterol in humans (-10 ± 32 mg/dL, p < 0.001).
“low-density lipoprotein (LDL) cholesterol by 10 ± 32 mg/dL”
Humans5-6 months
Diabetes, obesity & metabolism
HbA1c
downin humans1
1 study
HbA1c
downin humans1
Phentermine + topiramate is linked with lower HbA1c in humans (-0.4 ± 0.9%, p < 0.001).
“the HbA1c decreased by 0.4 ± 0.9%”
Humans5-6 months
Diabetes, obesity & metabolism
Treatment cost
downin silico1
1 study
Treatment cost
downin silico1
Phentermine + topiramate decreases treatment cost in silico (compared with other anti-obesity medications) (nearly identical QALYs to other agents).
“Compared to other AOM, PpT was lowest cost treatment with nearly identical QALYs with other agents.”
In silicocompared with other anti-obesity medications
Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective
Nutrition, metabolism, and cardiovascular diseases : NMCD
Has phentermine + topiramate been tested in people?
0 of 23 about agingYes: 1 trial and 9 observational studies in people have been published, and 20 trials are registered.
Approved
Jul 17, 2012Obesity, Overweight, excess body weight
Repurposing
Phase 4Terminated2 trials
Phase 4Results posted4 trials
Phase 2Results posted1 trial
Phase 2Results posted1 trial
Phase 2Results posted1 trial
Phase 2Results posted1 trial
All 10Fewer
In trials
Hypothalamic tumor
Phase 2Active, not recruiting1 trial
Readouts due
- Jul 31, 2027
Stopped
NCT04531176TerminatedObesity
After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.
Who is developing phentermine + topiramate?
1 company: VIVUS.
- Companies
- VIVUSPhase 4blood pressure
Trial sponsors
Company8 trialsPhase 41,849 people
University of California-irvine
1 trialPhase 4120 people
1 trialPhase 474 people
Masonic Cancer Center, University of Minnesota
2 trialsPhase 2163 people
2 trialsPhase 2163 people
St. Jude Children's Research Hospital
1 trialPhase 2100 people
National Institute of Diabetes and Digestive and Kidney Diseases
1 trialPhase 247 people
Wake Forest University Health Sciences
1 trialPhase 225 people